UroGen Pharma Announces March 2020 Investor Conference Schedule
-
Tuesday, March 3 rd -
11:20 AM Eastern Time -
Boston, MA
Oppenheimer 30th Annual Healthcare Conference
-
Wednesday, March 18 th -
1:35 PM Eastern Time -
New York, NY
A live audio webcast of each event will be available on the Investors section of UroGen's website, www.urogen.com. A replay of each webcast will be available on the website for approximately two weeks.
About
UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s lead investigational candidates, UGN-101 (mitomycin gel) for instillation, and UGN-102 (mitomycin gel) for intravesical instillation, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. UroGen is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005069/en/
INVESTORS:
Senior Director, Investor Relations
Kate.Bechtold@urogen.com
914-552-0456
MEDIA:
BCW-UroGen@bcw-global.com
703-861-5654
Source:
INVESTORS:
Kate Bechtold
Senior Director, Investor Relations
Kate.Bechtold@urogen.com
914-552-0456
MEDIA:
Alice Sofield
BCW-UroGen@bcw-global.com
703-861-5654